Chemomab Therapeutics Ltd - ADR

NASDAQ:CMMB   4:00:00 PM EDT
2.10
+0.06 (+2.94%)
7:54:26 PM EDT: $2.00 -0.10 (-4.76%)
Earnings Announcements

Chemomab Therapeutics Reports Q3 Loss Of $0.035 Per Share

Published: 11/11/2022 11:12 GMT
Chemomab Therapeutics Ltd - ADR (CMMB) - Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update.
Chemomab Therapeutics Ltd Q3 Loss per Share $0.035.
Chemomab Therapeutics Ltd - Company Currently Expects Its Runway to Last Through Year-end 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.03

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.03

More details on our Analysts Page.